Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: Increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function

Circulation

Volumn 99, Issue 16, 1999, Pages 2171-2176

  Yamauchi Kohno, Rikako ^a   Miyauchi, Takashi ^b   Hoshino, Tomoko ^a   Kobayashi, Tsutomu ^b   Aihara, Hajime ^a   Sakai, Satoshi ^b   Yabana, Hideo ^a   Goto, Katsutoshi ^b   Sugishita, Yasuro ^b   Murata, Sakae ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Cardiomyopathy; Endothelin; Heart failure

Indexed keywords

ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; N [6 [2 (5 BROMO 2 PYRIMIDINYLOXY)ETHOXY] 5 (4 METHYLPHENYL) 4 PYRIMIDINYL] 4 (2 HYDROXY 1,1 DIMETHYLETHYL)BENZENESULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DETERIORATION; DOSE RESPONSE; DRUG MECHANISM; HAMSTER; HEART FAILURE; MALE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0033609032     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.16.2171     Document Type: Article

References (35)

1. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504-509.
2. Hiroe M, Hirata Y, Fujita N, Umezawa S, Ito H, Tsujino M, Koike A, Nogami A, Takamoto T, Marumo F. Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy. Am J Cardiol. 1991;68:1114-1115.
3. Ishikawa S, Miyauchi T, Sakai S, Yamaguchi I, Sugishita Y, Goto K. Elevated plasma endothelin-1 in young patients with pulmonary hypertension due to congenital heart diseases is decreased after successful surgical repair. J Thorac Cardiovasc Surg. 1995;110:271-273.
4. Margulies KB, Hildebrand FL Jr, Lerman A, Perrella MA, Burnett JC Jr. Increased endothelin in experimental heart failure. Circulation. 1990;82: 2226-2230.
5. Sakai S, Miyauchi T, Sakurai T, Kasuya Y, Ihara M, Yamaguchi I, Goto K, Sugishita Y. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure: marked increase in endothelin-1 production in the failing heart. Circulation. 1996;93: 1214-1222.
6. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation. 1994;89:1573-1579.
7. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
8. Suzuki T, Kumazaki T, Mitsui Y. Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro. Biochem Biophys Res Commun. 1993;191:823-830.
9. Suzuki T, Tsuruda A, Katoh S, Kubodera A, Mitsui Y. Purification of endothelin from a conditioned medium of cardiac fibroblastic cells using beating rate assay of myocytes cultured in a serum-free medium. J Mol Cell Cardiol. 1997;29:2087-2093.
10. Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Hiroi Y, Mizuno T, Maemura K, Kurihara H, Aikawa R, Takano H, Yazaki Y. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem. 1996;271:3221-3228.
11. Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, Nogami A, Marumo F, Hiroe M. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensm II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest. 1993;92:398-403.
12. B receptor antagonist. Circulation. 1996;93:2068-2079.
13. Ishikawa T, Yanagisawa M, Kimura S, Goto K, Masaki T. Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria. Am J Physiol. 1988;255(Heart Circ Physiol 24):H970-H973.
14. Ito H, Hirata Y, Hiroe M, Tsujino M, Adachi S, Takamoto T, Nitta M, Taniguchi K, Marumo F. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res. 1991;69:209-215.
15. Shubeita HE, McDonough PM, Harris AN, Knowlton KU, Glembotski CC, Brown JH, Chien KR. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes: a paracrine mechanism for myocardial cell hypertrophy. J Biol Chem. 1990;265:20555-20562.
16. Ono K, Tsujimoto G, Sakamoto A, Eto K, Masaki T, Ozaki Y, Satake M. Endothelin-A receptor mediates cardiac inhibition by regulating calcium and potassium currents. Nature. 1994;370:301-304.
17. + current in guinea pig ventricular cells. J Cardiovasc Pharmacol. 1996;27:12-19.
18. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 1996;384:353-355.
19. Teerlink JR, Goldhaber SZ, Pfeffer MA. An overview of contemporary etiologies of congestive heart failure. Am Heart J. 1991;121:1852-1853.
20. Gertz EW. Cardiomyopathic Syrian hamster: a possible model of human disease. Prog Exp Tumor Res. 1972;16:242-260.
21. Hoshino T, Yamauchi R, Kikkawa K, Yabana H, Murata S. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist. J Pharmacol Exp Ther. 1998;286:643-649.
22. Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M, Yano M, Yamaguchi I, Sugishita Y, Goto K. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res. 1993;73: 887-897.
23. Miyauchi T, Yanagisawa M, Tomizawa T, Sugishita Y, Suzuki N, Fujino M, Ajisaka R, Goto K, Masaki T. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet. 1989;2:53-54.
24. Miyauchi T, Kobayashi T, Yamauchi R, Hoshino T, Sakai S, Kikkawa K, Yabana H, Sugishita Y, Murata S, Goto K. Cloning of hamster preproendothelin-1 cDNA and its expression in the heart. J Cardiovasc Pharmacol. 1998;31(suppl I):S298-S301.
25. Chang KW, Laconi S, Mangold KA, Hubchak S, Scarpelli DG. Multiple genetic alteration in hamster pancreatic ductal adenocarcinomas. Cancer Res. 1995;55:2560-2568.
26. Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Macé B, Comoy E, Letac B, Thuillez C. Role of endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 1997;96:1976-1982.
27. Fraccarollo D, Hu K, Galuppo P, Gaudron P, Ertl G. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation. 1997;96:3963-3973.
28. Clozel M, Clozel JP, Hess P. Endothelin receptor antagonism: a new therapeutic approach in experimental hypertension. Circulation. 1993; 88(suppl I):I-316. Abstract.
29. Nishikibe M, Tsuchida S, Okada M, Fukuroda T, Shimamoto K, Yano M, Ishikawa K, Ikemoto F. Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci. 1993;52:717-724.
30. B receptors in rats. Biochem Biophys Res Commun. 1994;199:1461-1465.
31. B receptors. J Appl Physiol. 1996;81:1510-1515.
32. Prasad MR. Endothelin stimulates degradation of phospholipids in isolated rat hearts. Biochem Biophys Res Commun. 1991;174:952-957.
33. Yorikane R, Koike H. The arrhythmogenic action of endothelin in rats. Jpn J Pharmacol. 1990;53:259-263.
34. Hano O, Mitsuoka T, Matsumoto Y, Ahmed R, Hirata M, Hirata T, Mori M, Yano K, Hashida K. Arrhythmogenic properties of the ventricular myocardium in cardiomyopathic Syrian hamster, Bio 14.6 strain. Cardiovasc Res. 1991;25:49-57.
35. Kiowski W, Sütsch G, Hunziker P, Müller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995;6:732-736.